OxSonics

OxSonics Therapeutics is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on improving cancer treatment through innovative drug delivery systems.

Founded in 2013 as a spinout from the University of Oxford, OxSonics specializes in ultrasound-based technology designed to enhance the efficacy of oncology drugs, particularly for solid tumors. The company's flagship product, the SonoTran® Platform, utilizes low-intensity focused ultrasound to improve drug delivery. This proprietary system employs SonoTran Particles, which carry gas bubbles that, when activated by ultrasound, create a micro-streaming effect to guide therapeutic agents directly into tumor tissues. This approach increases drug penetration and distribution while potentially reducing toxicity to healthy tissues. OxSonics is actively engaged in clinical trials and has established partnerships with pharmaceutical companies to evaluate the platform's effectiveness with novel anti-cancer agents. OxSonics aims to provide scalable and life-changing treatments for patients with solid tumor cancers, bridging the gap between advanced imaging technology and effective cancer therapies.